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background: Immunosuppression after heart transplantation (HTX) usually consists of calcineurin-inhibitors (CNI), antimetabolites and steroids. 
Renal insufficiency (RI) is a major CNI related toxicity. CNI-free IS (CNIFIS) is a strategy to prevent RI. This study aimed to evaluate recovery of renal 
function and incidence of acute or chronic rejection using CNIFIS.
Methods: We reviewed 38 post-HTX cases (81% male, 18.4% female) switched to CNIFIS 119-5195 (mean 1391) days post surgery. Creatinine 
(Crea) was followed at 12 months after the change. Newly acquired dependency on chronic hemodialysis (cHD) at any time was recorded. We 
reviewed endomyocardial biopsies to detect acute cellular rejection (ACR) and coronary angiography reports to monitor transplant vasculopathy 
(TVP) at any time after discontinuation of CNI. Finally all cases with ACR under CNIFIS were reviewed in regards of steroid sensitivity, clinical course 
and the need for re-introduction of CNI.
results: Follow-up after switch to CNIFIS was 1-81 months. 7 patients (18.4%) died 216-1006 days after elimination of CNI (2 cancer, 5 sudden 
death). 4 patients (10.5%) required cHD (median time on CNI after HTX: 3407 days). Kidney function improved in 18 patients (47,4%), while in 5 
patients (13,5%) Crea remained stable and in 27 patients (18,4%) further deterioration occurred. A total of 23 patients (60.5%) had no ACR, 15 
patients (39.5%) experienced episodes of ACR (ISHLT 1990: A1 - A3). Of these 15 patients with ACR, 6 (40%) responded to steroids and remained on 
CNI-free regimen without further ACR, while 9 (60%) were resistant and had to be switched back on low-dose CNI. 12 patients (31.6%) showed no 
signs of TVP at any time, 6 (15.8%) developed TVP after CNI discontinuation, even on low-dose CNI, 6 patients (15.8%) had preexisting TVP and 14 
cases (36.8%) had insufficient data.
conclusion: Dependent on the time after HTX, CNIFIS is a promising strategy to prevent RI in the majority of patients. This however has to be 
traded with the serious risk of late ACR in a greater number of patients. CNI cessation might possibly account for sudden death or development of 
TVP. Therefore careful patient selection and close monitoring after cessation of CNI is mandatory.
